Polyomaviruses KI 
and WU in Immunoï¿¾compromised 
Patients with 
Respiratory Disease 
Thomas Mourez, Anne Bergeron, Patricia Ribaud, 
Catherine Scieux, RÃ©gis Peffault de Latour, 
Abdellatif Tazi, GÃ©rard SociÃ©, FranÃ§ois Simon, 
and JÃ©rÃ´me LeGoff
Polyomaviruses KI (KIPyV) and WU (WUPyV) were 
recently identifi ed, mainly in respiratory specimens from 
children. Among 200 patients with respiratory disorders adï¿¾mitted to Saint Louis Hospital, Paris, France, KIPyV was 
detected in 8% and WUPyV in 1%. KIPyV was signifi cantly 
more frequent among human stem cell transplant patients 
(17.8% vs. 5.1%; p = 0.01). 
Recently, 2 new, distinct polyomaviruses (PyVs), KI 
(KIPyV) and WU (WUPyV), were identifi ed in reï¿¾spiratory specimens, mainly from children <5 years of age 
with respiratory tract infections. The fi rst retrospective 
studies of respiratory specimens in Sweden and Australia 
showed a KIPyV prevalence of 1% and 2.5%, respectively 
(1,2). Studies conducted in Australia and the United States 
showed a WUPyV prevalence in respiratory specimens of 
3% and 0.7%, respectively (3). Further studies conducted 
in Canada and South Korea have shown similar frequencies 
(4,5). In this study, we examined the prevalence of KIPyV 
and WUPyV in immunocompromised patients with susï¿¾pected respiratory tract infections.
The Study
From January through June 2007, 265 respiratory samï¿¾ples were received in the laboratory of Saint Louis Hospital, 
Paris: 154 nasal aspirates (NA) and 111 bronchoalveolar 
lavage (BAL) specimens collected from 200 patients with 
suspected upper or lower respiratory tract infections. This 
hospital specializes in the management of immunocomproï¿¾mised patients. Respiratory samples were collected for the 
diagnosis of acute respiratory illness; 89% of samples were 
from immunocompromised patients. Their median age was 
46 years (range 3.6â€“85.3 years). Given the observational 
nature of the study, French law did not require ethical apï¿¾proval or informed consent.
The specimens were routinely tested for infl uenza A 
and B viruses, respiratory syncytial virus, and parainfl uenza 
viruses 1, 2, and 3 by immunofl uorescence assay (Imagen; 
DakoCytomation, Trappes, France). Specimens positive for 
KIPyV or WUPyV were tested for adenoviruses; human 
bocavirus; human rhinoviruses; human metapneumovirus; 
human coronaviruses OC43, 229E, NL63, HKU1; and huï¿¾man PyVs BK and JC by using PCR methods (6â€“11). Toï¿¾tal nucleic acid was extracted from 200 Î¼L of NA, BAL, 
or stool specimens by using the EasyMag System (bioï¿¾MÃ©rieux, Marcy lâ€™Etoile, France). KIPyV was detected 
with an in-house real-time PCR assay targeting the VP1
gene. The primers and hydrolysis probe were designed 
by using Primer Express 3.0 software (Applied Biosysï¿¾tems, Foster City, CA, USA). The fi nal reaction volume 
was 25 Î¼L and contained 12.5 pmol of SLKI-VP1s (5â€²-
GGAAATACAGCTGCTCAGGAT-3â€²) and SLKI-VP1as 
(5â€²-CTTTGATACTTGAACCGCTTTCCTT-3â€²), 6.25 pmol 
of corresponding probe SLKI-VP1PR (5â€²-6FAM-C
GTGACCCCACCCCTCATTACTGGTC-TAMRA-3â€²), 
12.5 Î¼L of TaqMan Universal Master Mix (Applied Biosysï¿¾tems), and 5 Î¼L of DNA extract. The reaction was run on 
a 7500 Real-Time PCR System (Applied Biosystems). The 
specifi city of positive specimens was confi rmed by using 
PCR and nested PCR with primers POLVP1â€“39F/POLVP1â€“
363R and POLVP1â€“118F/POLVP1â€“324R, as described 
(1). The PCR products were then sequenced and compared 
with the previously described sequences from Sweden and 
Australia (GenBank accession nos. EF127906, EF127907, 
EF127908, EF520287, EF520288, and EF520289). WUPyV 
was detected by PCR as described (3). PCR products with 
the expected molecular weights were sequenced by using 
primers AG0044 and AG0045 and compared to published 
sequences (GenBank accession nos. EF444550, EF444551, 
EF444552, EF444553, and EF444554) (3).
KIPyV was detected in 17 (6.5%) of the 265 respiraï¿¾tory samples and in 16 (8.0%) of the 200 patients. All cases 
were confi rmed by a nested PCR targeting another region 
of the VP1 gene. Twelve of the 17 PCR products were sucï¿¾cessfully sequenced, and all shared 100% homology with 
published sequences. WUPyV was detected in only 2 paï¿¾tients (1.0%). Genome sequencing showed 98% homology 
with reported WUPyV sequences.
Six KIPyV-positive patients (37.5%) had co-infections 
with other respiratory viruses, and 2 of them (12.5%) had 
a pulmonary bacterial infection (online Appendix Table, 
available from www.cdc.gov/EID/content/15/1/107-appT.
htm). One WUPyV-infected patient who exhibited acute 
respiratory failure had concomitant pneumonia caused by 
Pseudomonas aeruginosa infection. None of the 15 paï¿¾tients who were positive for KIPyV or WUPyV and tested 
for fungi had respiratory or blood samples positive for 
Aspergillus spp.
 Emerging Infectious Diseases â€¢ www.cdc.gov/eid â€¢ Vol. 15, No. 1, January 2009 107 
Author affi liation: HÃ´pital Saint Louis, Paris, France 
DOI: 10.3201/1501.080758

The clinical characteristics of the patients with KIPyV or 
WUPyV infection and their general outcome until December 
2007 are given in the online Appendix Table. All but 3 had 
well-identifi ed systemic immunosuppression. However, all 
had severe coexisting conditions. All KIPyV- and WUPyVï¿¾positive patients had acute respiratory disorders.
Eight KIPyV-positive patients had received allogeneic 
stem cell transplants; 5 of them had exhibited profound 
neutropenia in the 2 weeks before the respiratory sample 
was found to be positive. The detection of KIPyV was sigï¿¾nifi cantly more frequent among hematopoietic stem cell 
transplant (HSCT) recipients than among other patients 
(17.8% [8/45] vs. 5.1% [8/155], p = 0.01) (Table). Lung 
or sinus imaging was assessed by computed tomography 
scan for 12 KIPyV-positive patients. Lung parenchyma 
abnormalities were noted in 9 patients, and sinusitis was 
diagnosed for 2 patients.
Taking into consideration both the frequency of digesï¿¾tive symptoms in our patients and the former published deï¿¾tection of KIPyV in a stool sample, we looked for KIPyV 
infection in the available stool samples while the respiratoï¿¾ry samples were being assessed for KIPyV (1). Strikingly, 
3 of 4 samples tested were positive for KIPyV (with cycle 
threshold values of 35.0, 38.3, and 40.3). All were collected 
from HSCT recipients. In addition, 1 HSCT patient who 
experienced diarrhea demonstrated persistent excretion of 
KIPyV in 9 consecutive stool specimens collected between 
June and the end of November 2007 (data not shown).
Conclusions
This study shows the prevalence of KIPyV and 
WUPyV among immunocompromised patients with respiï¿¾ratory disorders. Previously, these 2 viruses had been obï¿¾served mainly in young children (1â€“3). Of the few adult paï¿¾tients with KIPyV or WUPyV infection mentioned in these 
studies, most were immunocompromised (3,12).
Considering the seemingly higher prevalence of KIPï¿¾yV in our population (8%), immunocompromised patients 
may be more susceptible to this PyV, as they are to JC and 
BK viruses (13â€“15). Results from previous reports suggest 
a similar frequency of both KIPyV and WUPyV infections 
being found in respiratory specimens, ranging from 1% to 
3%. In contrast, in our series, we found a likely difference 
between the prevalence of KIPyV (8%) and WUPyV (1%), 
which suggests that the replication or reactivation of the 2 
viruses in the respiratory tract may differ between immuï¿¾nocompromised and immunocompetent patients. However, 
this difference requires further investigation, in particular, 
by using similar real-time PCR assays. Notably, a signifi -
cantly higher prevalence of KIPyV infection was found 
among HSCT patients, which suggests that a profound 
T-cell defi ciency may be a factor in facilitating KIPyV 
replication.
As reported in other populations, our patients who 
yielded positive specimens for KIPyV or WUPyV had conï¿¾ditions ranging from a common cold to acute respiratory 
distress that required invasive ventilation. Respiratory coï¿¾infections, observed in other studies, had likely accounted 
for at least some clinical features. In the 7 of our patients in 
whom KIPyV was the sole pathogen detected in the respiraï¿¾tory tract, despite comprehensive screening for viruses, bacï¿¾teria, parasites, and fungi, clinical and radiographic patterns 
were varied. Some of the patients had only upper respiratory 
tract infections, notably sinusitis, whereas others had lung 
parenchyma abnormalities as defi ned by computed tomoï¿¾graphic scan imaging. However, due to the retrospective 
nature of the study, and therefore the lack of a control group 
of immunocompromised patients without respiratory sympï¿¾toms, the association of KIPyV infection with the occurï¿¾rence of respiratory disease cannot be stated defi nitively.
In conclusion, the seemingly higher frequency of KIPï¿¾yV shedding in immunocompromised patients (as observed 
with other PyVs) and the detection of KIPyV as a single 
pathogen in respiratory disease (e.g., as cytomegalovirus 
recurrence can lead to pneumonia in immunocompromised 
patients) together support a reactivation hypothesis. Neverï¿¾theless, a reinfection hypothesis cannot be excluded due to 
immunocompromised patientsâ€™ increased risk of acquiring 
viral infection from exogenous sources 
Controlled prospective studies of KIPyV shedding beï¿¾fore and during immunosuppression will help determine 
the pathogenic role of this virus. The clinical implication of 
KIPyV detection in stools and the mechanisms underlying 
the concomitant presence in gastrointestinal and respiraï¿¾tory tracts also deserve further analysis.
Acknowledgments
We thank F. Freymuth, P. Lebon, and A. Vabret for adï¿¾vice and technical assistance and for providing positive virus 
controls.
Dr Mourez is a virologist in the Laboratory of Microbiolï¿¾ogy, Saint Louis University Hospital, Paris. His research interests 
include the development of tests for the diagnosis of emerging 
respiratory viruses and the study of the circulation and molecular 
analysis of human respiratory viruses in pediatric and immunoï¿¾compromised patients.
DISPATCHES
108 Emerging Infectious Diseases â€¢ www.cdc.gov/eid â€¢ Vol. 15, No. 1, January 2009
Table. Frequency of KI polyomavirus detection in respiratory 
samples* 
KIV detection in respiratory 
samples, no. (%) 
Sample source Positive Negative Total 
HSCT patients 8 (17.8)â€  37 (82.2) 45 
Other patients 8 (5.2) 147 (94.8) 155 
Total 16 184 200 
*HSCT, hematopoietic stem cell transplantation. 
â€ È¤2
 test with Yates correction; p = 0.01. 

Polyomaviruses in Immunocompromised Patients
References
 1. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, 
Persson MA, et al. Identifi cation of a third human polyomavirus. J 
Virol. 2007;81:4130â€“6. DOI: 10.1128/JVI.00028-07
 2. Bialasiewicz S, Whiley DM, Lambert SB, Wang D, Nissen MD, 
Sloots TP. A newly reported human polyomavirus, KI virus, is 
present in the respiratory tract of Australian children. J Clin Virol. 
2007;40:15â€“8. DOI: 10.1016/j.jcv.2007.07.001
 3. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu 
G, et al. Identifi cation of a novel polyomavirus from patients with 
acute respiratory tract infections. PLoS Pathog. 2007;3:e64. DOI: 
10.1371/journal.ppat.0030064
 4. Abed Y, Wang D, Boivin G. WU polyomavirus in children, Canada. 
Emerg Infect Dis. 2007;13:1939â€“41.
 5. Han TH, Chung JY, Koo JW, Kim SW, Hwang ES. WU polyomaï¿¾virus in children with acute lower respiratory tract infections, South 
Korea. Emerg Infect Dis. 2007;13:1766â€“8.
 6. Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, 
Rocha V, et al. Disseminated adenovirus infections after allogeneic 
hematopoietic stem cell transplantation: incidence, risk factors and 
outcome. Haematologica. 2007;92:1254â€“7. DOI: 10.3324/haemaï¿¾tol.11279
 7. Savolainen C, Mulders MN, Hovi T. Phylogenetic analysis of rhinoï¿¾virus isolates collected during successive epidemic seasons. Virus 
Res. 2002;85:41â€“6. DOI: 10.1016/S0168-1702(02)00016-3
 8. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell 
A, Andersson B. Cloning of a human parvovirus by molecular 
screening of respiratory tract samples. Proc Natl Acad Sci U S A. 
2005;102:12891â€“6. DOI: 10.1073/pnas.0504666102
 9. Bellau-Pujol S, Vabret A, Legrand L, Dina J, Gouarin S, Petitjeanï¿¾Lecherbonnier J, et al. Development of three multiplex RT-PCR asï¿¾says for the detection of 12 respiratory RNA viruses. J Virol Methï¿¾ods. 2005;126:53â€“63. DOI: 10.1016/j.jviromet.2005.01.020
10. Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. Deï¿¾tection of the new human coronavirus HKU1: a report of 6 cases. 
Clin Infect Dis. 2006;42:634â€“9. DOI: 10.1086/500136
11. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van 
Damme-Lombaerts R. Polyomavirus infection in pediatric renal 
transplant recipients: evaluation using a quantitative real-time PCR 
technique. Pediatr Transplant. 2004;8:485â€“92. DOI: 10.1111/j.1399-
3046.2004.00211.x
12. Norja P, Ubillos I, Templeton K, Simmonds P. No evidence for an 
association between infections with WU and KI polyomaviruses and 
respiratory disease. J Clin Virol. 2007;40:307â€“11. Epub 2007 Nov 7. 
DOI: 10.1016/j.jcv.2007.09.008
13. Shapiro S, Robin M, Esperou H, Devergie A, Rocha V, Garnier F, et 
al. Polyomavirus nephropathy in the native kidneys of an unrelated 
cord blood transplant recipient followed by a disseminated polyomaï¿¾virus infection. Transplantation. 2006;82:292â€“3. DOI: 10.1097/01.
tp.0000226172.68372.f9
14. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect 
Dis. 2005;41:354â€“60. DOI: 10.1086/431488
15. Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali 
RK, Munivenkatappa R, et al. Polyomavirus BK versus JC repliï¿¾cation and nephropathy in renal transplant recipients: a prospective 
evaluation. Transplantation. 2007;84:323â€“30. DOI: 10.1097/01.
tp.0000269706.59977.a5
Address for correspondence: JÃ©rÃ´me LeGoff, Laboratoire de Microbiologie, 
HÃ´pital Saint-Louis 1, Ave Claude Vellefaux 75010 Paris, France; email: 
jerome.le-goff@sls.aphp.fr
 Emerging Infectious Diseases â€¢ www.cdc.gov/eid â€¢ Vol. 15, No. 1, January 2009 109 
The print journal is available at no charge to public health professionals
YES, I would like to receive Emerging Infectious Diseases.
Please print your name and business address in the box and return by fax to 
404-639-1954 or mail to
 EID Editor
 CDC/NCID/MS D61
 1600 Clifton Road, NE
 Atlanta, GA 30333
Moving? Please give us your new address (in the box) and print the number of 
your old mailing label here_______________________________________
	


All material published in Emerging Infectious Diseases is in the 
public domain and may be used and reprinted without special 
permission; proper citation, however, is required.

